HMN-214 – 1 mg

Brand:
Cayman
CAS:
173529-46-9
Storage:
-20
UN-No:
De Minimis - 3077 / 9

HMN-214 is an orally bioavailable prodrug form of HMN-176, an indirect inhibitor of polo-like kinase (PLK) activity that inhibits proliferation of a variety of cancer cells.{43655,43656} HMN-214 decreases the expression of multidrug resistance gene 1 (MDR1) in AB-A.1 cells and in tumors isolated from mice bearing multidrug-resistant KB-A1 xenografts.{43656} HMN-214 (20 mg/kg per day) reduces tumor volume in PC3, WiDr, and A549 mouse xenograft models.{43655} It does not decrease nerve conduction velocity or compound action potential amplitude in rabbit sciatic nerves in vivo when administered at a concentration of 30 mg/kg per day.  

 

Available on backorder

SKU: 26210 - 1 mg Category:

Description

A prodrug form of the PLK inhibitor HMN-176; decreases MDR1 expression in AB-A.1 cells and in tumors isolated from mice bearing multidrug resistant KB-A.1. xenografts; reduces tumor volume in PC3, WiDr, and A549 mouse xenograft models at 20 mg/kg per day; does not induce nerve toxicity in rabbit sciatic nerves in vivo at 30 mg/kg per day


Formal name: N-[(4-methoxyphenyl)sulfonyl]-N-[2-[(1E)-2-(1-oxido-4-pyridinyl)ethenyl]phenyl]-acetamide

Synonyms:  IVX-214

Molecular weight: 424.5

CAS: 173529-46-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|Plks||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Multidrug Resistance